Thermoluminescent chip detector for in vivo dosimetry in pelvis and head &amp; neck cancer treatment

Leal, Marcela A.; Viegas, C.C.B.; Viamonte, A.; Campos, A. de; Braz, Delson; Clivland, Paul

doi:10.1016/j.apradiso.2009.12.027

Cited by 6 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This implies that 100% of the measured dose was within ±5% and 92% was within the recommended acceptable level of radiotherapy dose delivery of ±3%, which is for the average midpoint dose of 5 fractions. This result is comparable to the in-vivo dosimetry of pelvis cases using TLD in literature [6,7]. Further the % deviation from the prescribed dose is independent of the patient thickness which justifies the fact that the table can be used effectively for any patient thickness.…”

Section: Resultssupporting

confidence: 77%

Estimation of midpoint dose for cervical cancer patients using EPID

Balan

Chandrasekaran

Ramasubramanian

et al. 2018

Polish Journal of Medical Physics and Engineering

View full text Add to dashboard Cite

Purpose: To estimate the midpoint dose delivered to cervical cancer patients treated by conventional technique using Electronic Portal Imaging Device (EPID). Materials and Methods: Clinac 2100 equipped with aS500 EPID was used in this study. A methodology was developed to generate a Gy/Calibration Unit (CU) look up table for the determination of midpoint dose of patients. 25 patients of cervical cancer were included in this study and the delivered dose to the midpoint of the patients was estimated using EPID. The deviation between the prescribed and the measured dose was calculated and analysed. Results: EPID showed a linear response with increase in Monitor unit and the Gy/CU look up table was validated for different field sizes and depth. 250 fields were measured for 25 patients, 10 measurements per patient, weekly once and for 5 weeks. The results show that out of 250 measurements, 98% of the measurements are within ±5% and 83.2% are within ±3% for with a standard deviation of 1.66%. Conclusion: The outcome of this study proves the efficacy of this methodology for the estimation of midpoint dose using EPID with minimal effort, time and without any inconvenience to the patients unlike other in-vivo dosimeters.

show abstract

Section: Resultssupporting

confidence: 77%

Estimation of midpoint dose for cervical cancer patients using EPID

Balan

Chandrasekaran

Ramasubramanian

et al. 2018

Polish Journal of Medical Physics and Engineering

View full text Add to dashboard Cite

show abstract

Measurement and effects of MOSKIN detectors on skin dose during high energy radiotherapy treatment

Alnawaf

Butson

2012

Australas Phys Eng Sci Med

View full text Add to dashboard Cite

During in vivo dosimetry for megavoltage X-ray beams, detectors such as diodes, Thermo luminescent dosimeters (TLD's) and MOSFET devices are placed on the patient's skin. This of course will affect the skin dose delivered during that fraction of the treatment. Whilst the overall impact on increasing skin dose would be minimal, little has been quantified concerning the level of increase in absorbed dose, in vivo dosimeters produce when placed in the beams path. To this extent, measurements have been made and analysis performed on dose changes caused by MOSKIN, MOSFET, skin dose detectors. Maximum increases in skin dose were measured as 15 % for 6 MV X-rays and 10 % for 10 MV X-rays at the active crystal of the MOSKIN device which is the thickest part of the detector. This is compared to 32 and 26 % for a standard 1 mm thick LiF TLD at 10 × 10 cm(2) field size for 6 and 10 MV X-rays respectively. Radiochromic film, EBT2 has been shown to provide a high resolution 2 dimensional map of skin dose from these detectors and measures the effects of in vivo dosimeters used for radiotherapy dose assessment.

show abstract